Fritextsökning
Artiklar per år
-
De är bäst på patent
En internationell undersökning placerar Awapatent som nummer ett bland Sveriges patentbyråer.
-
Mikroskopiska miljoner
Ett Lundabaserat medicinteknikbolag har rest sju miljoner i riskkapital.
-
50 får gå från Pfizer - vd slutar
Pfizers vd Niklas Prager lämnar bolaget i samband med en omorganisation som träder i kraft i april.
-
Giftig örtmedicin stoppas
Ett örtbaserat kosttillskott ger leversvikt och misstänks ligga bakom flera dödsfall. 24 miljoner kapslar har sålts i Norden sedan 2004.
-
Han är en av de främsta i världen
Till vardags är han chef vid Oslos cancerkluster. Nu tar han plats i ett av världens mest exklusiva nätverk för unga ledare, i sällskap med bland andra golfproffset Tiger Woods, Norges Kronprins Haakon och Mark Zuckerberg som grundade Facebook.
-
Glutenintoleranta inte mer hjärtsjuka
Risken för leversjukdomar, sköldkörtelrubbningar och lymfom är dock större för dem som inte tål gluten, visar en ny stor undersökning som omfattat 15 000 svenskar.
-
Genjägare får ny vd
Det norska tjänsteföretaget Hunt Biosciences har utsett en ny vd.
-
Professor vid DTU utsedd
Hon är redan professor vid Köpenhamns universitet. Nu kan hon dessutom titulera sig adjungerad professor vid DTU.
-
Avhopp i Probis top
Bolagets styrelseordförande lämnar sitt uppdrag.
-
Nätspel lär idrottare vägra doping
En forskare vid Köpenhamns universitet får pengar från internationell antidopingkommitté, för ett nytt grepp att stoppa idrottsfusk.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
A smart company takes care of its best
Lundbeck didn't have to look far to find it's new international Director of Marketing. The talent was already in the house.
-
New member to Active board
The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be re-elected at the AGM in May.
-
Almost 150 will leave Coloplast
The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.
-
Researchers goes to the bottom of the brain
Swedish researchers have recently got new and deeper knowledge about the smallest part of the brain, the granule cells.
-
Biovitrum sells UK part
Biovitrum will soon spin-out a British subsidary
-
Oasmia gets a confirmation
FDA has granted Oasmia an expedited review status for Paclical Vet.
-
Biotech goes white and bright
White biotech could become Denmark's next blossoming business area.
-
Think outside the... brain
Riitta Hari from the Brain Research Unit at the Helsinki University of Technology has recently stated that the mind is more than just the brain.
-
Eli Lilly writes biotech fine history
The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.
-
Abbott expands by acquisition
An acquisition gives Abbott a leadership position in another large and growing medical device segment.
BREAKING